TSVT 2seventy bio
- 4.600
- +0.040+0.88%
- 4.550
- -0.050-1.09%
2seventy bio News
Leerink Partners Sticks to Their Buy Rating for 2seventy Bio (TSVT)
Bristol-Myers Posts Q1 Beat Despite Growth Headwinds
Express News | 2Seventy Bio Inc: Abecma (Idecabtagene Vicleucel, or Ide-Cel) Generated Approximately $52 Mln in U.S. Revenue During Q1 of 2024
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
Express News | 2Seventy Bio Said Co, Bristol Myers Squibb Announced That FDA Approved Use Of Suspension Lentiviral Vector For Manufacturing Of Abecma
2seventy Bio Is Maintained at Buy by Citigroup
2seventy Bio Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on 2seventy Bio, Raises Price Target to $12
2seventy Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/08/2024 118.18% Citigroup $9 → $12 Maintains Buy 03/18/2024 -9.09% Wedbush → $5 Reiterates Neutral → Ne
Positive Outlook for 2seventy Bio's ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics
Buy Rating and High Risk for 2seventy Bio: FDA Approval and Market Expansion Fuel Optimistic Outlook
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
Friday, the FDA approved Bristol-Myers Squibb Company (NYSE:BMY) and 2seventy Bio Inc's (NASDAQ:TSVT) Abecma (idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication
Bristol-Myers Squibb (BMY) and 2seventy bio (TSVT) said Friday that the US Food and Drug Administration has approved the expansion of the indication of the companies' myeloma treatment Abecma. The app
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
By Colin Kellaher Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with th
Express News | At An Estimated Median Duration Of Follow-Up Of 15.9 Months At The Primary PFS Analysis, Abecma More Than Tripled The Primary Endpoint Of PFS Compared With Standard Regimens
MGNX, SBNY and SLP Are Among After Hour Movers
2seventy Bio Finalizes Asset Sale and Executive Transition
2seventy Bio: Will No Exclusively Focused on Development and Commercialization of Abecma >TSVT
2seventy Bio: Will No Exclusively Focused on Development and Commercialization of Abecma >TSVT
2seventy Bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy Bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy Bio(TSVT.US) Director Buys US$203.99K in Common Stock
$2seventy bio(TSVT.US)$ Director Casdin Capital, LLC purchased 40,000 shares of Common Stock on Mar 26, 2024 at an average price of $5.0998 for a total value of $203.99K. This transaction involves oth
Analysis
Price Target
No Data
